- Roche (RHHBY, Financial) reports a 6% increase in Group sales to CHF 15.4 billion at constant exchange rates in Q1 2025.
- The Pharmaceuticals Division saw an 8% increase, reaching CHF 11.9 billion.
- Roche plans a USD 50 billion investment in US pharmaceuticals and diagnostics, creating over 12,000 jobs.
Roche (RHHBY) has demonstrated robust growth in Q1 2025, achieving a 6% increase in Group sales to CHF 15.4 billion at constant exchange rates. This growth was largely driven by the strong performance of its Pharmaceuticals Division, which rose by 8% to CHF 11.9 billion. Key medications such as Phesgo, Vabysmo, Xolair, and Hemlibra were significant contributors, collectively generating CHF 3.6 billion in sales.
Regionally, Roche observed a notable 18% sales increase in international markets, with the United States and Europe also showing appreciable growth of 6% and 5%, respectively. Despite a stable performance in the Diagnostics Division at CHF 3.5 billion, challenges arose in Asia-Pacific due to healthcare pricing reforms, resulting in a 15% decrease in that region.
Looking to the future, Roche plans an ambitious USD 50 billion investment in US pharmaceuticals and diagnostics over five years, expected to create more than 12,000 new jobs. This plan underscores Roche’s commitment to expanding its presence and capabilities in the US market.
In addition, several regulatory milestones were achieved, including FDA approval for Evrysdi tablets for spinal muscular atrophy and Susvimo for severe eye diseases, and EU approval for Columvi in combination with chemotherapy for blood cancer treatment. Roche also announced a collaboration with Zealand Pharma focused on weight loss treatments.
Roche's outlook for 2025 continues to be positive, with expectations of mid-single-digit sales growth and high-single-digit core earnings per share growth, reinforcing its strategic vision and market position.
